A Phase II, Randomized, Partially-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine (10 mg, 30 mg or 50 mg QD) in Patients Infected with Hepatitis B Virus.
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2015
At a glance
- Drugs Clevudine (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- 22 Oct 2005 New trial record.